よむ、つかう、まなぶ。
08 参考資料1－2 沈降ヘモフィルスｂ型ワクチンファクトシート［2.4MB］ (36 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_34803.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 予防接種基本方針部会 ワクチン評価に関する小委員会（第20回 8／29）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
57.
Song H, Bock H, Guadagno A, Costantini M, Baehner F, Kim YH, et al. 2015.
Safety of a Crm197-Conjugated Haemophilus influenzae type b vaccine in
Korean children. Southeast Asian J Trop Med Public Health 46:743-752
58.
World Health Organization. 2013. Safety of Quinvaxem (DTwP-HepB-Hib)
pentavalent vaccine.
http://www.who.int/immunization_standards/vaccine_quality/quinvaxem_pq
note_may2013/en/
59.
Huu TN, Phuong NT, Toan NT, Thang HV. 2015. Immunogenicity and Safety of
Quinvaxem ® (Diphtheria, Tetanus, whole-cell Pertussis, Hepatitis B and
Haemophilus Influenzae type b vaccine) given to Vietnamese infants at 2
to 4 months of age. Southeast Asian J Trop Med Public Health 46:753-763
60.
Aspinall S, Traynor D, Bedford P, Hartmann K. 2012. Lot-to-lot consistency
study of the fully liquid pentavalent DTwP-HepB-Hib vaccine Quinvaxem ®
demonstrating clinical equivalence, suitability of the vaccine as a booster
and concomitant administration with measles vaccine. Hum Vaccin Immunother
8:1109-1118
61.
Chen YG, Li J, Liu JF, et al. 2013. Study on safety and immunogenicity of Haemophilus
influenzae type b conjugate vaccine (polyribosylribitol phosphate-cross reacting
material 197) among the children aged 13-59 months. Chinese Journal of Vaccines
and Immunization 19 (in Chinese)
62．
イタリア保健省. 2013. 乳児のワクチン接種 (Vaccinazioni dell'infanzia).
http://www.salute.gov.it/portale/salute/p1_5.jsp?lingua=italiano&id=41&area=Va
ccinazioni
63.
World Health Organization. 2014.
Republic of Korea, 2014.
http://www.wpro.who.int/immunization/documents/epi_country_poster_2014_kor.pdf
.
33
Song H, Bock H, Guadagno A, Costantini M, Baehner F, Kim YH, et al. 2015.
Safety of a Crm197-Conjugated Haemophilus influenzae type b vaccine in
Korean children. Southeast Asian J Trop Med Public Health 46:743-752
58.
World Health Organization. 2013. Safety of Quinvaxem (DTwP-HepB-Hib)
pentavalent vaccine.
http://www.who.int/immunization_standards/vaccine_quality/quinvaxem_pq
note_may2013/en/
59.
Huu TN, Phuong NT, Toan NT, Thang HV. 2015. Immunogenicity and Safety of
Quinvaxem ® (Diphtheria, Tetanus, whole-cell Pertussis, Hepatitis B and
Haemophilus Influenzae type b vaccine) given to Vietnamese infants at 2
to 4 months of age. Southeast Asian J Trop Med Public Health 46:753-763
60.
Aspinall S, Traynor D, Bedford P, Hartmann K. 2012. Lot-to-lot consistency
study of the fully liquid pentavalent DTwP-HepB-Hib vaccine Quinvaxem ®
demonstrating clinical equivalence, suitability of the vaccine as a booster
and concomitant administration with measles vaccine. Hum Vaccin Immunother
8:1109-1118
61.
Chen YG, Li J, Liu JF, et al. 2013. Study on safety and immunogenicity of Haemophilus
influenzae type b conjugate vaccine (polyribosylribitol phosphate-cross reacting
material 197) among the children aged 13-59 months. Chinese Journal of Vaccines
and Immunization 19 (in Chinese)
62．
イタリア保健省. 2013. 乳児のワクチン接種 (Vaccinazioni dell'infanzia).
http://www.salute.gov.it/portale/salute/p1_5.jsp?lingua=italiano&id=41&area=Va
ccinazioni
63.
World Health Organization. 2014.
Republic of Korea, 2014.
http://www.wpro.who.int/immunization/documents/epi_country_poster_2014_kor.pdf
.
33